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Asthma varies considerably across the life course. Childhood asthma is known for its
overall high prevalence with a male predominance prior to puberty, common remission,
and rare mortality. Adult asthma is known for its female predominance, uncommon
remission, and unusual mortality. Both childhood and adult asthma have variable
presentations, which are described herein. Childhood asthma severity is associated
with duration of asthma symptoms, medication use, lung function, low socioeconomic
status, racial/ethnic minorities, and a neutrophilic phenotype. Adult asthma severity
is associated with increased IgE, elevated FeNO, eosinophilia, obesity, smoking, and
low socioeconomic status. Adult onset disease is associated with more respiratory
symptoms and asthma medication use despite higher prebronchodilator FEV1/FVC.
There is less quiescent disease in adult onset asthma and it appears to be less stable
than childhood-onset disease with more relapses and less remissions.
Keywords: asthma, pediatric, adult, childhood, airway
CHILDHOOD ONSET ASTHMA
Introduction to Childhood Asthma
Childhood asthma is not a singular disease, but rather a uniquely diverse disorder with variable
presentation throughout childhood. Asthma affects 8.3% of children in the United States and is the
most common chronic disease of childhood (1, 2). Childhood asthma is responsible for 50 billion
dollars in annual healthcare expenditures and is a major cause of emergency room visits, hospital
admissions, school absences, and loss of parental workdays (1–3).
Asthma is characterized by inflammation leading to bronchoconstriction, edema, and increased
mucous production in the airways. Interestingly, the disorder is more prevalent in boys in the
first decade of life. However, after puberty and in the second decade of life, it appears that
asthma is more prevalent in young women (4). Asthma disproportionately affects minority and
low-income children with African American and Hispanic children having the highest prevalence
rates, morbidity and mortality due to asthma (5, 6).
Asthma is considered a chronic disease of childhood however there are periods of time
during which disease can go into remission or resolve altogether. Important risk factors for the
development of childhood asthma have been identified. The phenotypes of childhood asthma
and varied presentations are best defined through the periods of the pediatric life course and are
described herein.
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Childhood Asthma Risk Factors
The perinatal period has been implicated in the development
of childhood asthma. Several cohort studies have unveiled risk
factors for the development of asthma in offspring, with factors
that span from genetic and environmental risk factors to features
such as child’s sex and presence of atopy.
Genetic Risk Factors
The genetics of asthma are an emerging and complicated
topic. Multiple genes are thought to contribute to asthma
and rapidly changing technology continues to build our
current understanding of the genetic risk factors for asthma
development. This is a complex topic that we will only
briefly describe herein. Genome-wide Association Studies
(GWAS) have dramatically improved our understanding of
asthma susceptibility genes. Briefly, the following genes have
been determined to have significant association with asthma
susceptibility: the 17q21 locus with the ORMDL3 and GSDML
genes, the IL33 gene on chromosome 9p24, theHLA- DR/DQ gene
on chromosome 6p21, the IL1RL1/IL18R1gene on chromosome
2q12, the WDR36/ TSLP gene on chromosome 5q22 and
the IL13gene on chromosome 5q31 (7). Interestingly, GWAS
have shown evidence that loci may be specific to racial/ethnic
populations, such PHYNN1 observed in African-Americans
with asthma (8). However, as with other common diseases, for
individuals, only a small degree of heritability of asthma can be
explained by the genes observed in GWAS. Therefore, emerging
and multi-genetic approaches are needed to further study the
genetic susceptibility to asthma (7).
Environmental Risk Factors
Environmental perinatal risk factors are also important to
consider for childhood asthma. Maternal tobacco smoking
during pregnancy has been shown to increase the risk of
childhood asthma (9). Maternal diet in pregnancy has also been
implicated as an asthma risk factor with reports of maternal
diets higher in vitamin E, zinc, and polyunsaturated fatty acids
as protective against the development of childhood asthma
(10–12). In contrast, high sugar intake in thematernal diet during
pregnancy has been associated with increased risk of asthma in
offspring (13). Other maternal dietary factors have been studied
but with less conclusive results including the intake of vitamin D,
vitamin C, and a Mediterranean diet. Other perinatal risk factors
for childhood asthma that have been reported are neonatal
jaundice, maternal preeclampsia, and cesarean section delivery,
all which have been associated with higher risk of childhood
asthma development (14–16).
Ultimately gene-environment interactions (the genetic-
environmental axis) are critical for the development of asthma
in a child (8).
Natal Risk Factors
Chronic lung disease of prematurity is known to increase the
risk of asthma development in children (17). Specifically, extreme
preterm birth (23–27 weeks gestation) is associated with an
increased risk of asthma into young adulthood (18). Additionally,
cesarean section delivery as mode of delivery (16, 19) and low
birth weight have been associated with asthma diagnosis in mid-
childhood with symptoms persisting into adult life (20).
Sex
Boys are more likely to develop childhood asthma, as compared
with girls, at least until the point of puberty. This has been
explained by smaller airway size in boys compared with girls
under age 10 years, which predisposes to worsened airway
reactivity, as compared with girls of the same age, height and
weight (21).
Family History
Both maternal and paternal histories of asthma are associated
with increased risk of asthma in offspring. Interestingly,
maternal asthma history is more strongly associated with asthma
development in the child (22).
Medical History
Presence of atopy (having IgE antibodies to specific allergens)
is strongly associated with childhood asthma (23). Specifically
the “atopic march” is a pattern that is described clinically in
individuals with atopic disease. This “atopic march” begins as
atopic dermatitis (or eczema) in infancy, develops on to allergic
rhinitis (or hayfever) and then asthma later in childhood (24).
Specific indoor allergen sensitization in early life have been of
interest with regard to asthma development. Sensitization to
house dust mite, alternaria mold, and cockroach allergens have
been associated with increased risk of asthma (25, 26), whereas
early life exposure to cat and dog allergens have been associated
with both increased and decreased risk of asthma in different
studies (27, 28).
Medication Exposure
Exposures to antibiotics (29) and antipyretics (30) in infancy have
been described to be associated with increased risk of developing
childhood asthma however the data has been conflicting and the
study results have been concerning for uncontrolled confounding
bias. Therefore, further studies are warranted before conclusions
can be made about these associations.
Presentation of Asthma: Early Childhood
(0–6 Years)
Studies of asthma’s natural history have shown that almost
80% of cases begin during the first 6 years of life (31). The
symptoms of pediatric asthma in this age group are varied and
not specific to asthma making the diagnosis challenging. The
primary symptoms of asthma in infancy and early childhood
include cough, both dry and productive (albeit young children
rarely expectorate), wheeze, shortness of breath, and work of
breathing. Asthma symptoms are a result of airway inflammation,
bronchospasm, airway edema, and airway mucous gland
hypertrophy. Interestingly, these symptoms can also present with
a multitude of other pediatric diseases including respiratory tract
infections and congenital airway anomalies posing a diagnostic
challenge. It is well-established that asthma in this age group is
frequently under-diagnosed and undertreated (32, 33).
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Often, clinicians including pediatric asthma specialists
(pulmonologists and allergists) define asthma in this age
group as symptoms of airway inflammation that reverse with
bronchodilator therapy. However, given the diagnostic challenge
in this age group, the Asthma Predictive Index (API) was
developed to guide the diagnosis of childhood asthma in children
under age 3 years (34). The API has limited sensitivity but
reasonable specificity. The API major criteria were defined as
physician-diagnosed eczema or parental asthma. The minor
criteria were defined as physician-diagnosed allergic rhinitis,
wheezing apart from colds, and serum eosinophilia>4%. Positive
loose index were defined as parental report of wheezing on
surveys at age 2 or 3 years and either 1 major or 2 minor criteria.
Positive stringent index was defined as frequent wheezing on
surveys at age 2 or 3 years and either 1 major or 2 minor criteria.
Children with a positive loose index were found to be four times
more likely to have active asthma on surveys at age 6, 8, 11,
and 13 years (sensitivity 42%, specificity 85%). Children with a
positive stringent index were seven times more likely to have
asthma on a school-age survey (sensitivity 16%, specificity 97%).
The API is most useful for its negative predictive value and thus,
when negative, is an essential tool for determining who is not
likely to go on to having later asthma. While not a perfect tool,
a slightly modified API, with criteria of a higher score of frequent
wheezing and replacing “physician-diagnosed allergic rhinitis”
with skin prick testing, is endorsed by the US National Asthma
Education and Prevention Program Expert Panel Report 3 for use
in diagnosing asthma in this young age group (35).
Often in this age group, particularly over 0–3 years, symptoms
are virally triggered rather than allergically triggered. Infants will
often have very few symptoms until they experience an upper
respiratory infection, which can trigger a significant and severe
inflammatory cascade.
In children, the initial few years following asthma diagnosis
are critical. For both physician visits and hospitalizations, the
number of children having had a second asthma encounter
peaked at 3 years after diagnosis and then stabilized (36). Overall,
75% of children had a second asthma episode within 3 years
of diagnosis, suggesting that it takes ∼3 years to control and
stabilize asthma episodes (36). The frequency of asthma episodes
soon after diagnosis points to the need for attentive follow-
up and aggressive management and education strategies in the
early years (36). The mainstays of therapy in this age group are
based on recurrence of wheezing symptoms or in severity. For
those children with recurrent wheezing or significant morbidity
with multiple emergent visits, oral steroid courses or hospital
admissions, inhaled corticosteroids are the main therapy. There
are a limited number of pathophysiological asthma studies in
children under 5 years of age, which presents a challenge in the
evidence base for the management of childhood asthma.
Presentation of Asthma: Late Childhood
(7–11 Years)
By this age, children can more reliably perform spirometry, and
reversible airway obstruction on spirometry can be a helpful
diagnostic tool. However, it is important to note that in children
with asthma, spirometry values can be normal despite significant
disease and morbidity (37). Therefore, in children, spirometry is
often used as a monitoring tool for asthma symptoms after the
diagnosis has been established through other assessments (38).
Symptoms in this age group transition more from discrete
episodes of wheezing in response to viral infections to allergic
triggered exacerbations. In this age group, exercise-induced
symptoms manifest more clearly which may be due to a true
change in the clinical presentation of asthma in this age group
or also due to sports and exercise becoming a more discreet
activity for children of this age wherein caretakers are able to
appreciate the symptoms of dyspnea or cough with exertion. In
children who avoid or develop a loss of interest in exercise or
physical activities, it is important to consider that asthma may
be underlying.
Some children in this age group will have few day-to-day
symptoms, but have severe asthma attacks in response to specific
triggers such as cold weather, cigarette smoke, or seasonal
allergies. Virally triggered asthma exacerbations occur in this age
group but less often than in the 0–6 year age range and may
contribute to the lower rates of healthcare utilization in this age
group as compared with younger years of 0–4 years (2).
Presentation of Asthma: Adolescence
(12–18 Years)
Puberty has an interesting impact on childhood asthma,
specifically relating to sex. Prior to puberty, asthma risk is
higher among male children. At the time of puberty, the risk
of asthma is approximately equal between males and females,
and after puberty, girls have a higher risk of asthma (39). Some
of these differences could be explained by the differences in
airway development between the sexes. The fetal lung is less
developed in boys from 16 to 26 weeks, measured by mouth
movements that reflect fetal breathing, a critical determinant
of lung development. In the last 4 weeks of gestation, airway
resistance is higher in males (21). Boys up to 10 years old appear
to have smaller airways in relation to lung size as compared with
girls of the same age, height, and weight (21). After puberty,
smaller airway caliber is then observed in the female sex (39). The
known sex differences in asthma may also be due to other factors
such as hormonal effects, genetic susceptibility, immunologic
response, and differences in consultation practices and health-
seeking behaviors by sex (4, 40).
Asthma symptoms in this age group are most predominantly
shortness of breath with exertion, wheezing in response to
triggers, chest pain, chest tightness, and cough. In this age group,
asthma symptoms can significantly impact sleep, school, sports,
and social engagements. Children are more aware of symptoms
in this age range and often feel more embarrassment or stigma
around using an inhaler and in particular a spacer, often leading
to under treatment of asthma symptoms (40).
Remission is common in adolescence, with remission rates
reported at 16–60% (41). Factors that have been implicated in an
increased probability of asthma remission include mild disease
and minor airway inflammation before adolescence, male sex,
and the absence of allergic sensitization (42, 43).
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Wheezing and Asthma Phenotypes in
Childhood
Childhood wheezing phenotypes have been explored given that
nearly 50% of children experience wheezing before age 1, yet
only 20% of those children progress to have continued wheezing
later in childhood (44). While there are several longitudinal
birth cohorts that have described wheezing phenotypes, we will
describe the classifications according to the earliest of these
studies: the Tucson Children’s Respiratory Study and the most
recent systematic comparison of the clinical and epidemiologic
classifications (45).
WHEEZING PHENOTYPES (44, 45):
Never/Infrequent Wheeze
This Describes Children who do not Experience any Wheezing.
The Transient Wheeze
This describes children who have their first wheeze before the
age of 3 years with resolved wheezing by age 6 years. Transient
wheeze is not strongly related to atopy and genetic risk; there are
only mild impairments in lung function in this phenotype, and
medication use is very uncommon (45).
The Persistent Wheeze
This describes children who experience first wheezing before age
3 year, however go on to have continued wheezing at age 6 years.
Persistent wheeze was strongly related to the asthma risk locus on
chromosome 17, however this phenotype appears to be unrelated
to environmental determinants. Interestingly, bronchodilator
administration dramatically improved any compromises in lung
function for children with this phenotype (45).
Intermediate Onset Wheeze
This describes children who experience rare (or no) wheezing
before 18 months of age, but persistent wheeze thereafter.
Intermediate-onset wheeze has associations with atopy, but only
to pollen sensitization (45).
The Late Onset Wheeze
These children develop wheezing between age 3 and 6 years. Late-
onset wheeze is strongly associated with fractional exhaled nitric
oxide levels and sensitization to inhaled allergens at 6 years and
at 4 years. There appears to be severe and irreversible reduction
in lung function in this phenotype and asthma medication use is
common (45).
CHILDHOOD ASTHMA CLINICAL
PHENOTYPES
Asthma Diagnosis (45)
Physician’s diagnosis of asthma at least once per lifetime
or recurrent diagnoses of spastic, obstructive, or asthmatic
bronchitis as reported by the parents at age 6 years.
Frequent Wheeze (45)
Wheeze on a monthly basis for at least 1 year between age 1 and
6 years.
Unremitting Wheeze (45)
Having symptoms between wheezing episodes or having wheeze
without a cold at least once between age 1 and 6 years.
Recurrent Unremitting Wheeze (45)
Having symptoms between wheezing episodes or wheeze without
a cold for 2 or more years between age 1 and 6 years.
Multi-Trigger Wheeze (45)
Having at least 2 common asthma triggers leading to wheeze
between ages 3–6 years.
Episodic Wheeze (45)
Wheezing episodes associated only with viral upper respiratory
infection between age 1 and 6 years.
Severe, Difficult to Control Asthma,
Steroid-Resistant Asthma
Children that do not seem to respond to standard treatment
are referred to as severe or difficult to control asthma, and
these children experience substantial morbidity from asthma
symptoms. To classify a child into this phenotype, the first step is
to exclude an incorrect diagnosis, poor adherence to treatment,
or incorrect technique with an inhaler and spacer (46, 47).
Supervised asthma therapy programs can be extremely useful in
managing asthma symptoms and reducing healthcare utilization
for children with poor medication adherence and inhaler and
spacer technique (48, 49). It is important to differentiate between
severe therapy-resistant asthma and difficult-to-treat asthma
due to comorbidities Difficult to treat asthma is a much more
common reason for persistent symptoms and exacerbations and
can be managed if comorbidities, such as allergic rhinitis and
chronic exposure to asthma triggers, are directly targeted. Home
visiting programs and assessment of the school environment are
important features of the evaluation for children with concern
for chronic exposure to asthma triggers (50–52). Children with
persistent symptoms and exacerbations despite correct inhaler
technique and good medical adherence to standard asthma
therapy (steroid-resistant or therapy resistant asthma) should be
referred to an asthma specialist to consider more potent biologic
therapies such as anti-IgE, anti-IL-5, or anti-IL-13 therapies and
further evaluation (47).
Eosinophilic Predominant
Eosinophilic inflammation is considered to be themain feature of
allergic asthma in children (53). Sputum eosinophils and serum
periostin are biomarkers that have been proposed for defining
which children with asthma will respond to anti-IgE, anti-IL-
5, or anti-IL-13 asthma treatment (54). However bronchoscopy
is not routinely done in children with asthma, therefore serum
eosinophils are often the least invasive and most common
biomarker utilized to indicate the presence of eosinophilic
predominant asthma and help predict responsiveness to inhaled
corticosteroid therapy (55).
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Neutrophilic Predominant
While initially most childhood asthma was thought to be
eosinophilic in nature, a neutrophilic predominance has emerged
as an important phenotype. In this phenotype, children generally
have low IgE levels, low serum and sputum eosinophil counts
with very little allergic symptoms. Neutrophil-predominant
asthma is the most severe asthma phenotype with poor
corticosteroid response (54) and may explain some of the
children who have not respond well to standard asthma therapy.
OTHER CHILDHOOD ASTHMA CLINICAL
PRESENTATIONS:
In clinical practice, there are different clinical presentations of
symptoms that point to an underlying diagnosis of childhood
asthma, and clinical improvement can occur in response to
starting a child on preventive asthma therapy, such as a daily-
inhaled corticosteroid and use of bronchodilator therapy for
acute episodes.
Recurrent Croup
Croup, inflammation of the upper airway, which presents as
barky cough and stridor, is a common isolated entity in infancy
and early childhood. However, the presence of recurrent croup
may indicate the presentation of underlying asthma in childhood.
Recurrent croup has been shown to be a risk factor for childhood
asthma and airway hyperreactivity (56) as well as strongly
associated with bronchial asthma in children (57).
Middle Lobe Syndrome
Asthma in children is associated with significant atelectasis and
specifically with middle lobe and lingula collapse, (58) and often
infants and children who ultimately develop asthma, present as
recurrent atelectasis, or mucous plugging in the right middle lobe
and lingula. In contrast to adults, children are thought to have
higher resistance to collateral airflow, possibly due to increasing
number and size of collateral alveolar ventilation, through pores
of Kohn and bronchoalveolar Lambert’s channels, that develop
from birth to adulthood (59). This theory is supported by the
finding that pores of Kohn are absent in newborns, and develop
around 4 years of age, with the greatest numbers of pores of Kohn
found in the apical portions of upper and lower lobes, as well
as in peribronchial, perivascular, and subpleural areas, (60, 61),
leaving the right middle lobe and lingual vulnerable to atelectasis
and mucous plugging, particularly in children with asthma.
Recurrent Pneumonia
In a child with recurrent multi-lobar pneumonia, with a normal
immune function evaluation, asthma should be considered as
an underlying cause of the recurrent chest infections. Many
children referred to specialty care with recurrent chest infections
will be found to have undiagnosed or undertreated asthma.
Often the history reveals that most have recurrent episodes of
cough, wheeze and breathlessness, with trigger factors of upper
respiratory tract infections, exercise, cold air, emotional upset, or
exposure to pets and other aero-allergens suggestive of asthma
(62). In several studies, asthma was the main underlying cause
for recurrent pneumonia in children (63).
Association Between Childhood Asthma
and COPD
Children with asthma have an increased risk of developing
chronic obstructive pulmonary disease (COPD) in adulthood.
Specifically, it has been shown that children who smoke tobacco
and also have asthma are at increased risk for developing low lung
function and COPD as adults, when compared to smokers who
did not have asthma in childhood (64).
Remission and Mortality in Childhood
Asthma
Asthma remission occurs most commonly between the ages of
14–21 years (65). However, large longitudinal studies have also
shown that, among children who wheezed before age 3 years,
more than 50% had stopped wheezing either by 6 years of age (44)
or by 12 years of age, (36, 66) depending on the study. Remission
rates of childhood asthma have been reported between 16 and
60% by early adulthood, according to prior longitudinal studies
(41, 65, 67). The wide variation in reported remission rates is
likely due to diverse study designs, varying follow-up periods, and
different study populations. In longitudinal studies, children with
the following characteristics had higher remission rates: episodic
asthma (rather than persistent asthma), milder initial asthma
severity, less allergic sensitization, less allergic rhinitis, less atopic
dermatitis, and male sex (36, 65).
While the morbidity of childhood asthma is significant,
fortunately, mortality from childhood asthma is rare with an
estimated 28 deaths per million children with asthma (2). As with
childhood asthma morbidity, there are grave racial disparities in
childhood asthma mortality, and black, and Hispanic children
suffer disproportionately from the highest mortality rates (2).
ADULT-ONSET ASTHMA
Introduction to Adult-Onset Asthma
Asthma is increasingly recognized as an umbrella term for a
heterogenous group of conditions that has been likened to the
term “arthritis” in Rheumatology—not a specific diagnosis but
a term that describes a diverse group of conditions clinically
and biologically (68). Some have suggested discarding the term
asthma altogether (69).
Asthma is a common condition amongst adults, estimated
to affect 235 million people worldwide, and is estimated to
cause more than 350,000 deaths per year (70). It carries a huge
economic, morbidity and mortality burden in both developing
and developed nations (70). Themortality in developed countries
from asthma has remained static for more than a decade and it is
clear that a better understanding and management of this diverse
group of conditions is required (71).
Asthma is considered a childhood disease by many but this is
erroneous as longitudinal studies have shown that approximately
half of middle aged patients with asthma have had onset in
adulthood rather than childhood (72–74). This proportion of
adult onset asthma increases with age (73). The annual incidence
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TABLE 1 | Comparison of childhood and adult asthma.
Feature Childhood asthma Adult asthma
Variable Phenotypes Yes Yes
Symptoms Age 0–6 years: Cough,
wheezing, acute episodes of
dyspnea and increased work of
breathing
Age 6–11 years: cough,
wheezing, dyspnea or cough
with exertion
Age 11–18 years: cough,
wheezing, dyspnea, dyspnea on
exertion, chest tightness,
chest pain
Shortness of breath,
wheeze, chest
tightness and cough.
Allergic
bronchopulmonary
aspergillosis:
Above symptoms plus
sputum production.
Aspirin exacerbated
respiratory disease:
Above symptoms plus
nasal polyps and
sensitivity to aspirin.
Sex predominance Males < 10 years Females
Remission Common Rare
Factors associated
with severity
Asthma duration, medication
use, lung function, neutrophilic
phenotype, low socioeconomic
status, racial/ethnic minorities
IgE, FeNO,
eosinophilia, obesity,
smoking, low
socioeconomic status
Mortality Rare Uncommon
of asthma amongst adults is estimated to be 0.5%, similar to
the incidence in childhood and it remains unclear as to whether
adult-onset asthma is a different disease to that occurring in
childhood (75).
The area of asthma phenotyping amongst adults has been
developing at a rapid rate. Initially clinical phenotypes were
identified that help to categorize asthma in adults by clinical
traits including that of early and late onset, obese vs. non-
obese, and atopic vs. non-atopic (76, 77). More recently biologic
phenotyping has been increasingly recognized and performed
clinically, particularly with the availability of targeted biologic
agents, and this phenotyping is currently based on presence of
allergic or eosinophilic inflammation although this is a rapidly
evolving field (68). This has led on to more complex molecular
phenotyping which may well-inform future precision medicine
in asthma (78).
The natural history of asthma occurring in adulthood is
complex because it is such a heterogenous disease. Despite the
complexities adult-onset asthma appears to run a different course
to that of childhood-onset disease where the majority of the
disease is mild and remission is common (79) (Table 1). In adults
with asthma remission is uncommon and disease is often more
severe and progressive (80).
Phenotypes
Although there has been significant development and research
into asthma phenotypes in the past two decades the concept
has developed slowly and to some remains controversial (68).
In this context phenotype refers to subtypes of the disease that
have recognizable properties produced by interactions of the
genotype and the environment (81). From this concept has
emerged the concept of asthma endotypes where a biologic
pathway is identified that leads to the clinical phenotype
(82). Phenotypes and endotypes are an attractive concept but
unfortunately patients rarely fit into these classifications perfectly
with many factors that muddy the waters including presence
of comorbidities and confounders. For this reason a more
pragmatic concept of treatable traits has gained momentum (83).
Rather than attempting to categorize people with asthma, this
approach seeks to describe traits associated with an individual’s
asthma including clinical aspects, biological characteristics, and
comorbidities (83).
Phenotypes of asthma can be broadly categorized into clinical,
biological, and molecular although there is considerable overlap
between these and, ultimately, it is the combination of the three
that is likely to form the asthma phenotypes of the future.
Clinical
The attempt to classify asthma is not a new concept with
clinical phenotypes having been described since the 1940s (84,
85). One of the oldest approaches to clinical phenotyping was
between allergic (extrinsic) and non-allergic (intrinsic) asthma
that described two clinically distinct entities—that of early onset
asthma associated with sensitization to allergens and other
allergic diseases, and that of the poorly understood late onset
asthma that was non-allergic (84). Because these phenotypes did
not confer specific management there was little clinical utility in
the distinction.
More recently different clinical phenotypes have been
identified by unbiased cluster analysis of cohorts of asthma
patients, with the most detailed analysis performed on the
Severe Asthma Research Program cohort in the United States
(76, 77). This analysis resulted in the development of five
clinical groups, two with early onset, and three other groups.
The two groups with early onset are those with normal lung
function requiring minimal controller medications, and those
with preserved lung function but requiring more medications
and healthcare utilization (77). The first of the other three
groups comprises obese women with late onset non-atopic
asthma, moderately impaired lung function and frequent oral
corticosteroid use for asthma exacerbations. The remaining two
groups comprise those with severe airflow obstruction and
bronchodilator responsiveness, and a less well-defined group
with variable ability to attain normal lung function, age of onset,
atopic status, and use of oral steroids.
These phenotypes have been further refined with the addition
of biologic markers to five groups; early-onset allergic, late-onset
eosinophilic, exercise-induced, obesity-related and neutrophilic
(68). These will be discussed in more detail below.
The extension of the development of more detailed clinical
phenotypes is whether these phenotypes represent distinct
clinical entities with different treatment strategies. There is
considerable work being done currently in this space.
There are, however, a number of clinical phenotypes
amongst adults with asthma that are distinct, including
those with occupational asthma, aspirin-associated asthma,
and asthma associated with other conditions such as allergic
bronchopulmonary aspergillosis and chronic obstructive airways
disease (COPD) (86–88). Some of these subtypes have more
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developed clinical characteristics associated with them, biological
mechanisms, management, and natural history.
Biologic
As phenotyping of asthma has progressed there has been
progressive attempts to describe the endotype, or biologic
pathway, behind different clinical phenotypes.
The most developed of these is the distinction between the
presence or absence of Type 2 inflammation (T2) in asthma (89).
It has long been recognized that for many, but not all, patients
with asthma there is upregulation of Type 2 inflammation. This is
characterized by an stimulus at the level of the airway epithelium
that results in production of IL-25, IL-33, and thymic stromal
lymphopoietin (TSLP) that stimulate release of IL-4, IL-5, and
IL-13 and, in turn eosinophils and antibodies that lead to the
pathogenic airway changes characteristic of asthma (90). This
upregulation of the Type 2 inflammatory response in asthma has
important clinical implications because this inflammation tends
to be responsive to corticosteroids.
Unlike in children, amongst adults there is a significant
proportion of non-T2 high disease. This group of patients is
less well-understood than their T2-high disease counterparts
and accounts for a significant proportion of mild-moderate
adult-onset asthma (91). Although these patients are poorly
characterized there are significant implications for treatment as
they tend to be less steroid responsive than those with T2-high
disease and it is unclear what the best treatment strategy for these
patients is (92).
Most asthma, even amongst adults, still appears to have T2-
high etiology (76, 77). Even clinical subtypes such as exercise-
induced asthma appears to be T2-mediated (93). With regard
to the asthma phenotypes discussed above, different biologic
mechanisms have been described. Early-onset allergic asthma
is the predominate form in children, varies in severity, is
associated with allergic symptoms and other allergic diseases
and characterized by elevated specific IgE, T2 cytokines and is
responsive to inhaled corticosteroids (68). A similar form does
also occur in adults. Exercise-induced asthma can be diagnosed
in children or adults and is characterized by relatively mild,
intermittent symptoms. Biologically there is mast cell activation,
T2 high and it tends to respond to leukotriene antagonists, beta
agonists and IL-9 agonists (94).
Molecular
More recently molecular phenotyping has also been attempted.
In one study on mild to moderate asthma patients upregulated
genes were identified in epithelial brushings to molecularly
classify those with T2-high and T2-low asthma (90). Those
with T2-low asthma were found to have similar gene-expression
patterns to the control group (90). Those with T2-high asthma
on genetic profile were found to have increased IL-13, IL-5,
eosinophils, and mast cells as well as more atopy (95).
Molecular phenotyping has potential implications for
treatment with those with T2-high asthma based on genetic
profile having a response to inhaled corticosteroids and those
with T2-low disease having no response (90, 95).
Adult Phenotypes of Asthma
Late Onset Eosinophilic
Characterized by both clinical and biologic features of later
onset, predominately female, and elevated sputum and serum
eosinophils. Late-onset eosinophilic asthma is defined clinically
by adult-onset, severe disease and is associated with sinusitis
and less allergic sensitization compared to early onset disease.
Biologically patients have increased IL-5 and IL-13 in the airways
and elevated eosinophils in the sputum and serum (96–98). No
cut off for sputum and serum eosinophils have been universally
agreed upon however it is generally accepted that a sputum
eosinophil count of >2% or a serum eosinophil count of >300
cells/uL (or in some cases >150 cells/uL) indicates eosinophilic
asthma (99–101). Despite a high prevalence of positive skin prick
tests this form of asthma appears to be less allergic but is often
associated with sinusitis, nasal polyps, and aspirin exacerbated
respiratory disease (96). A family history of asthma is seen less
frequently than those with early onset asthma (96). This type of
asthma can be relatively steroid resistant but biologic therapies
targeting T2 pathways have been shown to be highly effective in
this group of patients (102–105).
Obesity-Related Asthma
Obesity-related asthma is not well-understood. It is unclear
whether it is a comorbidity common in asthma that confers
greater likelihood of breathing pattern disorder, gastroesophageal
reflux and deconditioning or whether it is the driver for a
proinflammatory state that results in asthma (106–109). Higher
body mass index (BMI) is associated with increased levels
of TNFa, IL-6, and leptins and less eosinophils, FeNO and
corticosteroid responsiveness (108, 109). Clinically there appears
to be a group of older non-allergic, obese females who have
significant symptoms but minimal healthcare utilization (76,
77). The interaction between BMI and eosinophils is more
complex, with those who have early onset T2-high asthma
having a correlation between duration of asthma and BMI, lower
activity levels, and corticosteroid exposure that does not appear
to exist in those with T2-low disease (110). Bariatric surgery
has been shown to improve outcomes in asthma patients with
late onset, non-allergic asthma but not in those with allergic
disease (111).
Neutrophilic Asthma
Neutrophilic asthma is poorly defined and there is no consensus
about the characterization of this entity. Adding to the confusion
is the fact that corticosteroid treatment commonly suppresses
eosinophils and causes neutrophilia making the assessment
of corticosteroid-dependant patients difficult (112–114). The
clinical phenotype remains controversial and inconsistent but
has been suggested to be that of adult-onset, severely obstructed
with only partial reversibility and a high healthcare utilization
(77, 78). Smokingmay also play a role. Furthermore, neutrophilic
asthma can occur in those with elevated eosinophils conferring
a particularly severe clinical phenotype (115). These patients
tend to be less corticosteroid responsive and other treatment
strategies have been tried including use of macrolide antibiotics
(116). Although IL-17 has been suggested as a potential
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therapeutic target in neutrophilic asthma a biologic targeted
at this interleukin did not result in improvement in asthma
control and so far this area remains disappointing (117, 118).
The initial disappointment with targeted therapies such as the
anti-IL-17 and anti-TNFa agents has been tempered by positive
preliminary results with a newer biologic agent targeting TSLP
that has showed promise in Phase 2 studies in a non-eosinophilic
group (119, 120).
Aspirin-Associated Asthma
Aspirin-associated asthma, a subset of aspirin exacerbated
respiratory disease (AERD) has been described for many years
(85). It tends to occur in adulthood at an average age of
34 years and is more common amongst females (86). This is
a subset of late-onset eosinophilic asthma and is associated
with sinusitis, nasal polyps and sensitivity to cyclooxygenase-1
inhibitors including aspirin (86). Biologically it is characterized
by upregulation of the cysteinyl leukotriene pathway and elevated
eosinophils (96). Molecularly genes related to the leukotriene
pathway have been implicated and periostin, a biomarker of IL-13
activity, has been found in nasal polyps present in patients with
AERD (97, 121). These patients are often relatively corticosteroid
resistant, requiring high doses for control, but can be responsive
to leukotriene antagonists (122, 123). More recently biologic
therapies that target T2 pathways including IL-4, IL-13, and IL-5
have been shown to be effective in patients with asthma and nasal
polyps (124–126).
Allergic Bronchopulmonary Aspergillosis
Allergic bronchopulmonary aspergillosis (ABPA) was first
described in the 1950s and is caused by allergic sensitization
to fungal colonization of the lower airways with Aspergillus
fumigatus (127, 128). It occurs in 1–2% of asthma patients,
although has been detected in up to 13% of the population
in asthma clinics, predominately adults, and causes asthma
exacerbations, deterioration of pulmonary function, mucous
plugging, central bronchiectasis, and transient pulmonary
infiltrates with characteristic biologic features including
elevated total and Aspergillus-specific IgE as well as peripheral
eosinophilia (88, 128, 129). The diagnosis is based on presence
of asthma, proximal bronchiectasis, sensitization to Aspergillus,
and an elevated total IgE (129). It is important to diagnose
ABPA because of the progressive nature of the bronchiectasis in
the absence of treatment (129). The mainstay of treatment for
ABPA is systemic corticosteroids and, in some cases, antifungal
agents (88).
Link Between Early Transient Wheeze and COPD
There is a link between childhood asthma and COPD (130).
Both childhood asthma and childhood wheezy bronchitis have
been associated with an increased risk of COPD in adults
(131). Severe childhood asthma has been shown to confer a
32 times higher risk of COPD in adults despite the fact that
just under half of those diagnosed with COPD in this cohort
had never smoked (132). Early transient wheeze has been
thought of as a benign condition but did significantly increase
risk of the presence of COPD in adulthood with long term
follow up (131).
Asthma-smoking associations have been described in both
early and late onset asthma (133). Smoking remains a key
risk factor for airflow obstruction in normal and asthmatic
individuals, however the risk appears to be greatest in those with
late onset disease (74).
Natural History
The natural history of asthma in adults is different to that of
asthma in children with less remission of adult-onset asthma than
that occurring in childhood.
Many adults with asthma have childhood-onset disease that
has persisted and there have been many risk factors that
predict the persistence of asthma into adulthood including
the severity of childhood disease, the presence of bronchial
hyperresponsiveness, atopy, exposure to allergens and a parental
history of asthma (134–136). In longitudinal studies the amount
of wheeze in early adolescence has been shown to predict the
severity in later life. In an Australian-based cohort of second
graders with wheezing of various severities followed up to age
50 there was remission of asthma in 64% of those with mild
wheezy bronchitis or wheezy bronchitis, 47% of those with
persistent asthma and only 15% of those with severe asthma
(137). In this group risk factors for persistence of asthma at
age 50 were severe childhood asthma, childhood allergic rhinitis,
and female sex (137). In another longitudinal cohort 73% with
few symptoms at 14 years had little or no asthma 14 years later
whereas 68% of those with frequent wheeze at 14 years still had
asthma 14 years later (138). Most who had frequent wheeze at
21 still had wheeze at 28 years and of those with infrequent
wheeze at 21 years 44% had worsened at 28 years (138).
These findings have been replicated in more recent studies—
three quarters of children with childhood asthma will outgrow
the disease by middle age although overall our understanding
of the natural history of childhood asthma remains poorly
understood (139).
Adult onset asthma has many different forms and the
risk factors appear to be different to that of childhood-onset
disease. Compared to childhood asthma, major associations
with adult-onset disease are female sex, current smoking, and
low socio-economic status but not atopy or a family history
of asthma (74). Other risk factors include; clinical—historical
symptoms of wheeze, rhinitis, chronic cough; physiological—
lower lung function, bronchial hyperresponsiveness, lower
height; comorbidities—higher BMI, nocturnal gastroesophageal
reflux disease, habitual snoring, IgE reactivity to Timothy
grass; and lifestyle—low physical activity amongst men
(75, 107, 140–144). The evidence for smoking as a risk factor
is mixed with two large cohort studies from Australia and
Sweden showing that this is a risk factor for adult-onset
asthma and other studies showing that it doesn’t appear
to be (74, 75, 141, 144).
In a large cohort with severe asthma with onset between 14
and 55 whowere followed for 10 years 83% had less severe asthma
at 10 years (145). Risk factors for the persistent presence of severe
asthma was low socioeconomic status, high comorbidity burden
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and high adherence tomedications in the first year after diagnosis
(145). In this cohort sex and other risk factors important in
childhood asthma were not associated with continued presence
of severe asthma (145).
The sex differences in asthma amongst different age groups
are interesting. Amongst children males are more commonly
affected by asthma than females and male sex is a risk factor
for developing asthma (39). Around the time of puberty this
risk becomes equal and after puberty the risk in females
is greater than that amongst males, an observation partially
but not fully explained by women’s smaller airway caliber in
adults (39). There is emerging evidence of the association
between female hormonal changes and asthma that may
partially explain the female predominance of asthma after
puberty (146, 147).
Some factors that don’t appear to be risk factors for adult onset
asthma include level of education, atopy (either baseline or newly
positive skin prick tests), occupational exposures or maternal
asthma (141, 143, 144).
Despite the differences in risk factors for adult-onset asthma
compared to childhood onset disease the prevalence of asthma
amongst adults was shown to be increasing in the second
half of the twentieth century similar to that of childhood
asthma (73, 148).
Young Adults
In those who develop asthma as young adults the natural history
appears to be more similar to that of childhood asthma with
atopy an important a risk factor and more remissions (149).
The 23 year follow up of one study in the US examined asthma
incidence in participants 23 years after college, finding that the
cumulative prevalence of asthma increases with age and that
three-quarters of those who had asthma at the first visit were
in remission or had improved symptoms at 40 years (149).
Only a small number who had asthma at the baseline visit were
worse (149).
Middle Age
Many patients are diagnosed with asthma in middle age and
this disproportionately affects women. In fact for women most
asthma occurring in middle age is adult-onset asthma and by 40
years more than half of asthma in women is adult onset (73). The
proportion of adult onset asthma was even higher in women who
were obese, non-atopic, ever smokers, white, and lower socio-
economic status (73, 74). In contrast for men by 50 years only one
third of asthma is adult-onset asthma (73). Therefore it is clear
that adult-onset asthma is more common in women (73). Overall
those with adult onset asthma are more likely to experience
symptoms including wheeze, new rhinitis, snoring, and weight
gain (143). Those with adult onset disease are also more likely to
have a decline in lung function than those with childhood onset
disease (143).
Older Adults
For those who first experience asthma in their senior year
atopy does not appear to be a risk factor (149). Older adults
who develop asthma have a similar incidence as younger
people of ∼100 per 100,000 (150). However, disease severity
is worse amongst older adults developing asthma compared
to younger people and is also more progressive with poorer
lung function and more fixed airflow obstruction (151). This
poorer lung function and more fixed airflow obstruction
is thought to be largely the result of the more common
presence of comorbid lung diseases such as bronchiectasis,
pulmonary fibrosis, and COPD (151). Older adults with
asthma are less likely to experience remission than their
younger counterparts (151).
Remissions
In adults with asthma remissions have been found to be
uncommon after the second decade of life and particularly
uncommon in those between 30 and 60 years old (79). In
adult-onset, non-allergic asthma remission is especially unusual
occurring in only 20% of patients (152). Risk factors for those
not achieving remission were severe symptoms, impaired lung
function, and a comorbid diagnosis of chronic bronchitis or
emphysema (79). Amongst adults with asthma who do remit
relapses have been found to be common and increase until the age
of 70 years particularly if there was persistent symptoms despite
remission (79, 153).
Lung Function
Lung function has been found to decline in some but not all
adult-onset asthma patients (154–156). In those with persistent
asthma there is generally a decline in lung function that
eventually leads to a restrictive pattern of spirometry (157). Adult
lung function is influenced by initial FEV1 and sex, with a
larger decline observed amongst females, but not initial asthma
severity or allergic sensitization (136). Lower lung function
has also been found to be related to presence of bronchial
hyperresponsiveness (136).
In aspirin-exacerbated asthma a steady progress in severity has
been found (86). Rhinitis generally appears around the age of 30
years followed by asthma, aspirin sensitivity, then nasal polyps
(158). Women generally have more severe disease with earlier
onset, one third of patients are atopic and they tend to have an
earlier onset, and lower FEV1 (159).
The natural history of ABPA is variable with five stages
identified including acute, active; remission; recurrent;
chronic; and severe, end-stage disease (160). Early diagnosis
and treatment is associated with a reduced likelihood of
progressive disease (146, 160). Serum IgE level is often used
to track progress of disease and help to identify remission
and relapse of ABPA (160). Overall those with ABPA
have been observed to have a progressive decline in lung
function although there are those who undergo complete
remission (88).
Mortality
Thankfully mortality in asthma remain uncommon (71).
However mortality rates are not declining and in fact have
increased in some developed countries (71, 161). Asthma deaths
are more common amongst adolescents and young adults, those
of low socioeconomic status, black race, those with substance
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TABLE 2 | Asthma presentations across the lifecourse.
Age Presentation/Phenotype Description
Child Asthma diagnosis Physician’s diagnosis of asthma at
least once per lifetime or recurrent
diagnoses of spastic, obstructive, or
asthmatic bronchitis as reported by
the parents at age 6 years
Frequent wheeze Wheeze on a monthly basis for at
least 1 year between age 1 and 6
years
Unremitting wheeze Having symptoms between wheezing
episodes or having wheeze without a
cold at least once between age 1 and
6 years
Recurrent unremitting wheeze Having symptoms between wheezing
episodes or wheeze without a cold
for 2 or more years between age 1
and 6 years
Multi-Trigger wheeze Having at least 2 common asthma
triggers leading to wheeze between
ages 3 and 6 years
Episodic wheeze Wheezing episodes associated only
with viral upper respiratory infection
between age 1 and 6 years.
Severe asthma
Difficult to control asthma
Therapy resistant asthma
Asthma which is poorly controlled
based on frequent symptoms and
significant morbidity
Often due to incorrect diagnosis, poor
adherence to therapy, incorrect
inhaler/spacer technique,
uncontrolled comorbidities (allergic
rhinitis)
Poorly controlled asthma after ruling
out “Difficult to control asthma”
Eosinophilic predominant asthma Allergic asthma
Neutrophilic predominant asthma Non-allergic asthma
Recurrent croup Repeated episodes of croup
Middle lobe syndrome Repeated episodes of middle lobe
infiltrate or atelectasis
Recurrent pneumonia Repeated episodes of lung infection
Adult Late onset eosinophilic asthma Later onset, predominately female,
and elevated sputum and serum
eosinophils, associated with sinusitis
Obesity related asthma Associated with increased levels of
TNFa, IL-6, leptins, less eosinophils,
FeNO, and corticosteroid
responsiveness
Neutrophilic asthma Difficult to characterize, often severely
obstructed with only partial
reversibility and a high healthcare
utilization
Aspirin- associated asthma Subset of late-onset eosinophilic
asthma, associated with sinusitis,
nasal polyps, and sensitivity to
cyclooxygenase-1 inhibitors
Allergic bronchopulmonary
aspergillosis
Lower airway allergic sensitization to
Aspergillus fumigatus causing asthma
exacerbations, pulmonary function
deterioration, mucous plugging,
central bronchiectasis, and transient
pulmonary infiltrate
abuse, and are uncommon in young children and older adults
(162). Other risk factors for death include previous near-
fatal asthma, hospitalization or emergency department visit for
asthma in the past year, current or recent oral corticosteroid
use, non-adherence with inhaled corticosteroids, a history of
psychiatric disease, lack of a written asthma action plan and the
presence of comorbid food allergy (161). Overall the average life
expectancy for those with asthma is not reduced compared to the
general population (163). Elderly patients die more frequently
from respiratory diseases and are more at risk of complications
of medications (150).
Contrasts
It is difficult to accurately compare and contrast childhood
and adult-onset asthma due to existing gaps in the literature
and we acknowledge this limitation. Additionally because
some findings are reported more in adults, this does not
necessarily mean they are more prevalent, but rather a
possible manifestation of publication bias. Nevertheless, we
have provided a reflection of the similarities and differences
based on the currently available literature (Tables 1, 2). Adult
onset disease differed from pediatric onset disease in regard
to increased prevalence in women, non-atopic individuals, and
obese patients (73). Adult onset disease is associated with
more respiratory symptoms and asthma medication use despite
higher prebronchodilator FEV1/FVC (73). There is less quiescent
disease in adult onset asthma and it appears to be less stable
than childhood-onset disease with more relapses and less
remissions (73).
Severe asthma in children is distinct from severe asthma in
adults and approaches to severe asthma in adults should not be
extrapolated to children. In children the factors associated with
severity have been found to be asthma duration, medication use
and lung function rather than Type 2 inflammatory markers such
as increased IgE and elevated FENO that are markers of severity
in adult-onset disease (93).
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